daclizumab (Zinbryta)

From Aaushi
Jump to navigation Jump to search

Introduction

Withdrawn from worldwide market March 2018 due to reports of meningoencephalitis in Europe[5]

Indications

Adverse effects

Mechanism of action

More general terms

References

  1. Journal Watch 20(17):133, 2000
  2. Medical Knowledge Self Assessment Program (MKSAP) 16, American College of Physicians, Philadelphia 2012
  3. 3.0 3.1 Deprecated Reference
  4. 4.0 4.1 FDA News Release. May 27, 2016 FDA approves Zinbryta to treat multiple sclerosis. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm504000.htm
  5. 5.0 5.1 5.2 George J MS Drug Daclizumab Pulled from Worldwide Market Inflammatory encephalitis, meningoencephalitis reported in Europe . MedPage Today, March 2, 2018 https://www.medpagetoday.com/neurology/multiplesclerosis/71501
    FDA Drug Safety & Availability. March 14, 2018 FDA working with manufacturers to withdraw Zinbryta from the market in the United States. https://www.fda.gov/Drugs/DrugSafety/ucm600999.htm